COVID-19-associated phlebopathy as a current problem of modern phlebology

Введение. SARS-CoV-2 сопровождается развитием дисфункции венозного эндотелия, которая может привести к развитию персистирующей флебопатии нижних конечностей, снижаю щей качество жизни пациентов.

Цель. Оценить эффективность фармакологической терапии пациентов с постковидной флебопатией.

Introduction. SARS-CoV-2 is accompanied by the development of venous endothelial dysfunction, which can lead to the development of persistent phlebopathy of the lower limbs, reducing the quality of life of patients.

Objective. To evaluate the efficacy of pharmacological therapy in patients with postcocclusive phlebopathy.

Materials and methods. 178 patients (125 women), mean age 34.8 ± 3.2 years, who underwent SARS-CoV-2, for their first veno-specific complaints received micronized purified flavonoid fraction (MPFF) 1,000 mg per day for 90 days. Complaints were monitored using a 10-cm visual analog scale and the CIVIQ-20 questionnaire. All patients underwent ultrasound examination of the venous system of both lower extremities and photoplethysmography. Laboratory biochemical examination with determination of endothelial dysfunction marker levels was performed in 30 patients before and after treatment.

Results. After 90 days of phlebotropic therapy, there was a significant reduction in the severity of all venous-specific complaints, except for intradermal vein dilation. The global quality of life index increased from 64.4 ± 11.2 to 86.6 ± 9.1% (p < 0.001). There was an improvement in photoplethysmography (PPG) scores. Return blood-flow time and tibial venous muscle pump strength increased significantly (p < 0.05) by 4.3 s and 3.5%, respectively. The 30 patients who underwent biochemical examination in the first blood samples obtained from the great saphenous vein showed a significant increase in IL-1 concentration (7.8 ± 0, 7 pg/ml), IL-6 (18.7 ± 1.8 pg/ml), VEGF (187.8 ± 11.6 pg/ml), TNF (7.8 ± 0.9 pg/ml), histamine (22.4 ± 11.4 nmol/L) and hsCRB (5.4 ± 0.3 mg/L), indicating that a proinflammatory phenotype of venous endothelium was formed. After 90 days of MOFF administration, these indices significantly decreased. The levels of IL-1 and IL-6 decreased by 3.2 and 10.4 pg/ml, respectively, the values of VEGF and TNF decreased by 114.6 pg/ml and 2.9 pg/ml. There was a gradual normalization of histamine and hsCRB to 6.1 ± 4.1 nmol/L and 1.1 ± 0.9 mg/L.

Conclusions. The data obtained indicate that the appearance of veno-specific symptoms and syndromes in patients who have undergone SARS-CoV-2 may be due to the development of phlebopathy, the correction of which requires the use of pharmacological drugs with relevant mechanisms of action.

1. Rabe E., Guex J.-J., Puskas A., Scuderi A., Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.

2. Salim S., Machin M., Patterson B.O., Onida S., Davies A.H. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.

3. Andreozzi G., Signorelli S., Di Pino L., Garozzo S., Cacciaguerra G., Leone A., Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://pubmed.ncbi.nlm.nih.gov/11195857.

4. Bogachev V.Yu. Hormone- induced phlebopathy. A new problem of modern phlebology. Angiology and Vascular Surgery. 2002;(3):50–54. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2002/3/7.htm.

5. Tsoukanov Yu.T., Tsoukanov A.Yu. Clinical assessment of phlebopathy severity by specification of leg heaviness symptom. Angiology and Vascular Surgery. 2003;(1):67–70. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2003/1/8.htm.

6. Tsukanov Yu.T., Tsukanov A.Yu., Bazhenov V.N. The effect of oral contraceptives on the orthostatic diameter of lower limb major veins and its correction. Angiology and Vascular Surgery. 2008;(1):75–77. (In Russ.) Available at: https://www.angiolsurgery.org/ magazine/2008/1/10.htm.

7. Tsukanov Yu.T., Tsukanov A.Yu., Bazhenov V.N., Kornienko I.F., Vasilevich V.V. Drug-mediated correction of negative phlebotropic effects of hormone replacement therapy in women. Angiology and Vascular Surgery. 2009;(3):87–91. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2009/3/13.htm.

8. Serra R., Andreucci M., De Caridi G., Massara M., Mastroroberto P., de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.

9. Ali M., Spinler S. COVID- 19 and thrombosis: From bench to bedside. Trends Cardiovasc Med. 2021;31(3):143–160. https://doi.org/10.1016/j.tcm.2020.12.004.

10. Castro R., Frishman W. Thrombotic Complications of COVID- 19 Infection: A Review. Cardiol Rev. 2021;29(1):43–47. https://doi.org/10.1097/CRD.0000000000000347.

11. Del Turco S., Vianello A., Ragusa R., Caselli C., Basta G. COVID- 19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020;196:143–151. https://doi.org/10.1016/j.thromres.2020.08.039.

12. Nägele M., Haubner B., Tanner F., Ruschitzka F., Flammer A. Endothelial dysfunction in COVID- 19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014.

13. Anaya J.M., Rojas M., Salinas M.L., Rodríguez Y., Roa G., Lozano M. et al. Post- COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947. https://doi.org/10.1016/j.autrev.2021.102947.

14. Garg P., Arora U., Kumar A., Wig N. The “post- COVID” syndrome: How deep is the damage? J Med Virol. 2021;93(2):673-674. https://doi.org/10.1002/jmv.26465.

15. Pavli A., Theodoridou M., Maltezou H.C. Post- COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res. 2021;52(6):575–581. https://doi.org/10.1016/j.arcmed.2021.03.010.

16. Launois R., Mansilha A., Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.

17. Kuet M.L., Lane T.R., Anwar M.A., Davies A.H. Comparison of disease- specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.

18. Balakhonova T.V., Ershova A.I., Ezhov M.V., Barbarash O.L., Bershtein L.L., Bogachev V.Yu. et al. Focused vascular ultrasound. Consensus of Russian experts. Cardiovascular Therapy and Prevention (Russian Federation). 2022;(7):3333. (In Russ.) https://doi.org/10.15829/17288800-2022-3333.

19. Bonaventura A., Vecchié A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID- 19. Nat Rev Immunol. 2021;21(5):319–329. https://doi.org/10.1038/s41577-021-00536-9.

20. Zhang J., Tecson K.M., McCullough P.A. Endothelial dysfunction contributes to COVID- 19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med. 2020;21(3):315–319. https://doi.org/10.31083/j.rcm.2020.03.126.

21. Nicolaides A., Kakkos S., Baekgaard N., Comerota A., de Maeseneer M., Eklof B. et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S03929590.18.03999-8.

22. Kempuraj D., Selvakumar G.P., Ahmed M.E., Raikwar S.P., Thangavel R., Khan A. et al. COVID- 19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. Neuroscientist. 2020;26(5–6):402–414. https://doi.org/10.1177/1073858420941476.

23. Tajbakhsh A., Gheibi Hayat S.M., Taghizadeh H., Akbari A., Inabadi M., Savardashtaki A. et al. COVID- 19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345–357. https://doi.org/10.1080/14787210.2020.1822737.

24. Rabe E., Agus G., Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://pubmed.ncbi.nlm.nih.gov/25972136.

25. Kakkos S.K., Nicolaides A.N. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double- blind placebo- controlled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.

26. Mansilha A., Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.

27. Nicolaides A., Kakkos S., Baekgaard N., Comerota A., de Maeseneer M., Eklof B. et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S03929590.20.04388-6.

28. De Maeseneer M.G., Kakkos S.K., Aherne T., Baekgaard N., Black S., Blomgren L. et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.

29. Gallelli L., Zhang L., Wang T., Fu F. Severe Acute Lung Injury Related to COVID- 19 Infection: A Review and the Possible Role for Escin. J Clin Pharmacol. 2020;60(7):815–825. https://doi.org/10.1002/jcph.1644.

30. Idris S., Mishra A., Khushtar M. Phytochemical, ethanomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine. J Basic Clin Physiol Pharmacol. 2020;31(5). https://doi.org/10.1515/jbcpp-2019-0115.

31. Asiimwe I.G., Pushpakom S.P., Turner R.M., Kolamunnage- Dona R., Jorgensen A.L., Pirmohamed M. Cardiovascular drugs and COVID- 19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88(8):3577–3599. https://doi.org/10.1111/bcp.15331.

32. Gonzalez- Ochoa A.J., Raffetto J.D., Hernández A.G., Zavala N., Gutiérrez O., Vargas A., Loustaunau J. Sulodexide in the Treatment of Patients with Early Stages of COVID- 19: A Randomized Controlled Trial. Thromb Haemost. 2021;121(7):944–954. https://doi.org/10.1055/a-1414-5216.

33. Bogachev V.Yu., Boldin B.V., Turkin P.Yu. Horse chestnut extract. Update-2022. Consilium Medicum. 2022;(1):15–21. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/106361/80806.

34. Bednarz K., Borek A., Drzymala F., Rachwal K., Gabryel B. Pharmacological protection of vascular endothelium in acute COVID- 19. J Physiol Pharmacol. 2022;73(2). https://doi.org/10.26402/jpp.2022.2.01.